Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.
Actively Recruiting
Researchers are evaluating the glycemic efficacy, safety, and tolerability of ersodetug as an add-on treatment to standard care for patients with Tumor Hyperinsulinism Tumor HI, a condition causing low blood sugar due to hormone overproduction by certain non-removable tumors. This study focuses on patients whose hypoglycemia is not well controlled by existing therapies. It is a Phase 3, single-arm, open-label trial conducted across multiple sites in several countries. Participants will receive weekly doses of ersodetug at 9 mgkg for 8 weeks alongside their usual hypoglycemia treatments. The study has three periods an initial screening lasting up to 4 weeks, the 8-week treatment phase, and then either an end-of-study follow-up of about 20 weeks or an optional open-label extension lasting up to 3 years. The trial plans to enroll approximately 16 participants diagnosed with insulin- or IGF-producing tumors causing tumor HI. During the study, participants will be closely monitored with assessments of glucose infusion rates and other measures related to hypoglycemia control. Researchers will track changes in daily glucose infusion amounts and the time needed to stop intravenous glucose after starting ersodetug. Safety and tolerability will also be evaluated throughout the trial and follow-up periods. The total duration of participation could extend up to several years for those opting into the extension phase.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a group B streptococcus GBS vaccine in healthy pregnant women and their babies. This Phase 3 randomized, placebo-controlled, double-blinded study involves pregnant participants aged 49 or younger between 24 and 36 weeks of pregnancy, without major fetal abnormalities or infections such as HIV, syphilis, or hepatitis B. The study aims to understand how the GBS vaccine works and its safety profile for both mothers and infants. Participants will receive a single injection of either a multivalent GBS vaccine GBS6 or a placebo saline. After birth, a subset of infants will participate for up to 19 months, receiving standard vaccines including diphtheria toxoid-containing and pneumococcal vaccines as per local immunization schedules. Blood samples will be collected from infants after completing primary and booster vaccinations to assess immune responses. Pregnant participants will attend at least 3 to 4 visits with some allowed by telephone, with follow-up continuing for up to six months after delivery. Infants will be monitored for about 12 months, including a subset with extended follow-up to 19 months. Researchers will evaluate adverse events, antibody levels, and immune responses in both mothers and infants to assess safety and potential protection provided by the vaccine.
Actively Recruiting
Researchers are studying the anti-cancer effects of inobrodib combined with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma MM that no longer responds to existing treatments. This Phase II, open-label, multicenter study focuses on patients who have previously been treated with specific therapies including proteasome inhibitors, anti-CD38 monoclonal antibodies, pomalidomide, and bispecific T-cell engagers. The goal is to better understand the treatments activity and side effects in this patient group. Participants will receive 20 mg of inobrodib orally twice daily for 4 days followed by 3 days off in each 28-day cycle. Pomalidomide will be given at 4 mg once daily on days 1 through 21 of each cycle, and dexamethasone at 40 mg on days 1, 8, 15, and 22. Treatment will continue until disease progression, unacceptable side effects, or other withdrawal criteria are met. Approximately 100 patients will receive this combination treatment. During the study, participants will undergo regular assessments to evaluate treatment response based on International Myeloma Working Group criteria, including objective response rate measured by an independent review committee. Additional outcomes include duration and time to response, survival rates, and monitoring of any adverse events. Assessments will continue until disease progression or up to 48 months from enrollment, with safety monitored 28 days after treatment ends.
Actively Recruiting
Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of APC-0101, a surfactant for inhalation delivered with a special device, in preterm infants with Respiratory Distress Syndrome RDS. This phase 3, randomized, blinded, sham-controlled study compares infants treated with APC-0101 plus standard non-invasive respiratory support nCPAPNIV to those treated with the respiratory support alone. The study aims to better understand treatment outcomes in this vulnerable population. Participants are randomly assigned to either receive APC-0101 treatment with a dedicated delivery system alongside their current nCPAPNIV interface or to a control group where the nCPAPNIV interface is switched but no active surfactant is given sham. The study has two parts Part 1 follows infants until they reach 40 weeks post-menstrual age or are discharged from the neonatal intensive care unit, whichever comes first. In Part 2, infants are followed up until 24 months corrected age to assess longer-term outcomes. During the study, infants receive respiratory support and may be monitored with chest X-rays or lung ultrasounds to confirm RDS. Researchers will track treatment failure during the first 7 days of life and record the use of surfactant doses in the first 72 hours. The follow-up period includes evaluations up to 24 months to assess growth and health outcomes. Participation includes randomization, treatment administration, and extended follow-up visits to monitor safety and development.
Actively Recruiting
Researchers are evaluating a new multiomics assay called the Oricol Test, designed to detect colorectal cancer and significant polyps in patients showing symptoms and referred through the urgent suspected cancer pathway. The study aims to confirm known genetic, epigenetic, and microbiome biomarkers linked to colorectal cancer and high-risk adenomas, while also identifying additional rare biomarkers. The research also includes assessing the tests diagnostic performance, including sensitivity and specificity, and evaluating the health economics of delivering this diagnostic service through community centers compared to current pathways. The study involves collecting rectal mucus samples using the Oricol sampling device from patients referred for colonoscopy due to suspected colorectal cancer. This observational study focuses on analyzing these samples to develop and refine biomarker signatures associated with cancer and high-risk polyps. The research will measure various performance metrics of the assay over a 26-month period, alongside an economic assessment of the diagnostic approach. Participants will be adults aged 18 to 99 years who are referred via the urgent suspected cancer colorectal pathway and consent to participate. They will undergo rectal mucus sampling and possibly other clinical examinations like digital rectal exams. The study tracks biomarker presence and diagnostic accuracy while monitoring health economic outcomes. The total observation period for primary and secondary outcomes is 26 months, during which participants samples and data will be analyzed to evaluate the tests clinical utility and cost-effectiveness.